MXPA05010508A - Derivados de fosfato de productos farmaceuticos. - Google Patents

Derivados de fosfato de productos farmaceuticos.

Info

Publication number
MXPA05010508A
MXPA05010508A MXPA05010508A MXPA05010508A MXPA05010508A MX PA05010508 A MXPA05010508 A MX PA05010508A MX PA05010508 A MXPA05010508 A MX PA05010508A MX PA05010508 A MXPA05010508 A MX PA05010508A MX PA05010508 A MXPA05010508 A MX PA05010508A
Authority
MX
Mexico
Prior art keywords
phosphate derivatives
group
hormones
opioids
amino acids
Prior art date
Application number
MXPA05010508A
Other languages
English (en)
Inventor
Kannar David
Original Assignee
Vital Health Sciences Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vital Health Sciences Pty Ltd filed Critical Vital Health Sciences Pty Ltd
Publication of MXPA05010508A publication Critical patent/MXPA05010508A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6551—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring
    • C07F9/65512—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

De acuerdo a la invencion, se proporciona un complejo de un compuesto farmaceutico seleccionado del grupo que consiste de opioides, hormonas, anestesicos y agentes quimioterapeuticos que comprenden el producto de reaccion de: (a) uno o mas derivados de fosfato de uno o mas opioides, hormonas esteroides, hormonas tiroideas, anestesicos o agentes quimioterapeuticos que tienen un grupo funcional fenolico, alcohol primario, alcohol secundario o hidroxilo terciario y (b) un agente formador de complejo seleccionado del grupo que comprende surfactantes anfotericos, surfactantes cationicos, aminoacidos que tienen grupos funcionales nitrogeno y proteinas ricas en estos aminoacidos.
MXPA05010508A 2003-04-15 2004-04-14 Derivados de fosfato de productos farmaceuticos. MXPA05010508A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2003901813A AU2003901813A0 (en) 2003-04-15 2003-04-15 Pharmaceutical derivatives
PCT/AU2004/000492 WO2004091636A1 (en) 2003-04-15 2004-04-14 Phosphate derivatives of pharmaceutical products

Publications (1)

Publication Number Publication Date
MXPA05010508A true MXPA05010508A (es) 2005-11-16

Family

ID=31500850

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05010508A MXPA05010508A (es) 2003-04-15 2004-04-14 Derivados de fosfato de productos farmaceuticos.

Country Status (10)

Country Link
US (1) US20070042999A1 (es)
EP (1) EP1615650A4 (es)
JP (1) JP2006523623A (es)
KR (1) KR20060014370A (es)
CN (1) CN1774254A (es)
AU (2) AU2003901813A0 (es)
BR (1) BRPI0409761A (es)
CA (1) CA2521842A1 (es)
MX (1) MXPA05010508A (es)
WO (1) WO2004091636A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1262274C (zh) * 2000-11-14 2006-07-05 生命健康科学有限公司 磷酸盐衍生物复合物
AUPR549901A0 (en) * 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
MXPA04000654A (es) * 2001-07-27 2004-03-19 Vital Health Sciences Pty Ltd Terapia dermica usando derivados de fosfato de agente de transferencia de electrones.
CA2466536C (en) * 2001-12-13 2012-02-07 Vital Health Sciences Pty Ltd Transdermal transport of compounds
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
ATE534384T1 (de) * 2003-01-17 2011-12-15 Vital Health Sciences Pty Ltd Verbindungen mit proliferationshemmenden eigenschaften
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
WO2005051298A2 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
DE602005025979D1 (de) 2004-03-03 2011-03-03 Vital Health Sciences Pty Ltd Alkaloid-formulierungen
BRPI0513673B8 (pt) * 2004-08-03 2021-07-27 Vital Health Sciences Pty Ltd método para produzir um medicamento para aumentar a eficácia e o transporte dos compostos biologicamente ativos enteralmente administrados, e composição farmacêutica
KR20070108382A (ko) * 2005-03-03 2007-11-09 바이탈 헬스 사이언시즈 피티와이 리미티드 항암성 화합물
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
EP1893159B1 (en) * 2005-06-17 2015-09-30 Vital Health Sciences Pty Ltd. A carrier comprising one or more di- and/or monophosphate derivatives of electron transfer agents
KR20080085839A (ko) * 2005-12-23 2008-09-24 바이탈 헬스 사이언시즈 피티와이 리미티드 사이토킨 조절 특성을 가진 화합물
WO2008050836A1 (fr) * 2006-10-25 2008-05-02 Ajinomoto Co., Inc. Agent destiné à l'amélioration des effets secondaires d'un agent chimiothérapeutique
AU2009249069A1 (en) 2008-05-20 2009-11-26 Neurogesx, Inc. Carbonate prodrugs and methods of using the same
CN102149672A (zh) * 2008-05-20 2011-08-10 纽罗吉斯克斯公司 水溶性对乙酰氨基酚类似物
WO2011094814A1 (en) 2010-02-05 2011-08-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
MX2012011355A (es) 2010-03-30 2012-11-30 Phosphagenics Ltd Parche de suministro transdermico.
US9561243B2 (en) 2011-03-15 2017-02-07 Phosphagenics Limited Composition comprising non-neutralised tocol phosphate and a vitamin A compound
AU2016367708B2 (en) 2015-12-09 2022-07-14 Phosphagenics Limited Pharmaceutical formulation
WO2018094265A2 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
KR102647670B1 (ko) * 2016-12-21 2024-03-15 아베초 바이오테크놀로지 리미티드 방법
BR112019025659A2 (pt) 2017-06-05 2020-08-25 Viking Therapeutics, Inc. composições para o tratamento de fibrose
CA3094167A1 (en) 2018-03-22 2019-09-26 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
CN112824426B (zh) * 2019-11-21 2022-02-11 上海喀露蓝科技有限公司 一种别孕烯醇酮膦酰胺衍生物、其制备方法及其在医药上的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62195393A (ja) * 1986-02-21 1987-08-28 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造方法
DE3927113C2 (de) * 1989-08-17 1993-11-25 Dolorgiet Gmbh & Co Kg Mittel zur Behandlung von schweren Schmerzzuständen und Verfahren zu ihrer Herstellung
AU5171293A (en) * 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
MXPA01011597A (es) * 1999-05-14 2002-06-04 Swig Pty Ltd Proceso mejorado para la fosforilacion y compuestos producidos mediante este proceso.
CA2747954C (en) * 1999-12-03 2014-02-25 The Regents Of The University Of California Phosphonate compounds
CN1262274C (zh) * 2000-11-14 2006-07-05 生命健康科学有限公司 磷酸盐衍生物复合物
WO2002040033A1 (en) * 2000-11-14 2002-05-23 Vital Health Sciences Pty Ltd Formulation containing phosphate derivatives of electron transfer agents
MXPA04000654A (es) * 2001-07-27 2004-03-19 Vital Health Sciences Pty Ltd Terapia dermica usando derivados de fosfato de agente de transferencia de electrones.
CA2466536C (en) * 2001-12-13 2012-02-07 Vital Health Sciences Pty Ltd Transdermal transport of compounds
AU2002950713A0 (en) * 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier

Also Published As

Publication number Publication date
AU2003301764B8 (en) 2006-03-30
EP1615650A4 (en) 2006-06-14
CA2521842A1 (en) 2004-10-28
EP1615650A1 (en) 2006-01-18
CN1774254A (zh) 2006-05-17
BRPI0409761A (pt) 2006-05-09
JP2006523623A (ja) 2006-10-19
AU2003901813A0 (en) 2003-05-01
AU2003301764A1 (en) 2004-10-28
KR20060014370A (ko) 2006-02-15
WO2004091636A1 (en) 2004-10-28
US20070042999A1 (en) 2007-02-22
AU2003301764B2 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
MXPA05010508A (es) Derivados de fosfato de productos farmaceuticos.
AU1482102A (en) Complexes of phosphate derivatives
MXPA03000442A (es) Una formulacion medicinal en aerosol.
HUP0301688A3 (en) Amino alcohol derivatives, process for their preparation and pharmaceutical compositions containing them
YU28499A (sh) Novi preparati, lekova rastvorenih u vodi, za dobijanje aerosola bez potisnog gasa
HK1042444A1 (zh) 藥用噴霧製劑
GB2354007B (en) Pharmaceutical formulation of fluticasone propionate
IL148288A0 (en) Indolealkanol ester and indolealkylamide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
MY132882A (en) Use of cyp2d6 inhibitors in combination therapies
HK1002017A1 (en) Lyospheres comprising gonadotropin
PT1123120E (pt) Formulacao medicinal em aerossol
BR0111667A (pt) Novos compostos
HUP0200572A3 (en) Amine derivatives as protease inhibitors process for their preparation, pharmaceutical compositions containing them and their use
HUP0401241A3 (en) Novel cyclohexyl sulphones, process for their preparation and pharmaceutical compositions containing them
IL117091A (en) Methylphenyloxazolidinone derivatives pharmaceutical compositions containing the same and processes for the preparation threreof
IL150257A0 (en) Galactomaninan oligosaccharides, pharmaceutical compositions containing the same and methods for the production thereof
HUP0302770A3 (en) Tripeptidyl peptidase inhibitors, process for their preparation and pharmaceutical compositions containing them
AU2084801A (en) Antiviral medication
IL150528A0 (en) Ibuprofen containing active agent preparation
TW200505436A (en) Modified release pharmaceutical compositions and the processes for preparing them
PT1409021E (pt) Formulação compreendendo fulvestrant
HUP0302912A3 (en) Betha-thio-amino acids, process for their preparation and pharmaceutical compositions containing them
WO2002000191A3 (de) Bdellosomen
YU72802A (sh) Farmaceutske smeše koje sadrže oligosaharide, novi oligosaharidi i njihovo dobijanje
HUP0202305A3 (en) Novel vitamin d analogues, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FA Abandonment or withdrawal